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ABSTRACT 
Objective: The development and validation of LC-MS/MS method for quantification of Trazodone (a serotonin antagonist and reuptake inhibitor 
(SARI), which is a second generation antidepressant compound belonging to the class of phenyl piperazine) in human plasma is described.  
Methods: The method involves protein precipitation (extraction) using Trazodone d6 as an internal standard (IS). Chromatographic separation is 
achieved on Zorbax eclipse XDB C8 150×4.6 mm, 5 μm column with a mobile phase consisting of 2 mM ammonium formate (pH 3.0) and methanol 
(30:70 v/v) at a flow rate of 1.0 mL / min and the total run time was 2.5 minute. Detection was carried out by AB Sciex API 3200 tandem mass 
spectrometer using positive electro-spray ionization mode by multiple reactions monitoring method at m/z 372.00→176.10 and 378.20→182.10 for 
Trazodone and Trazodone d6 (ISTD) respectively with dwell times of 300 msecs for each of the transitions. 
Results: The standard curve was linear from 5.203 ng / mL to 3025.166 ng / mL with goodness of fit (r2) greater than 0.990 observed during the 
method validation batches. This assay allows quantification of Trazodone at a concentration as low as 5 ng / mL in human plasma. The observed 
mean recovery was 88% for the drug. 
Conclusions: The method described here is found to be simple, cost effective and suitable for the use in bioequivalence and bioavailability studies. 
Keywords: Trazodone, Trazodone d6, LC-MS/MS. 
 
INTRODUCTION 
Trazodone is chemically 2-{3-[4-(3-chlorophenyl)piperazin-1-yl] 
propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one. It is a serotonin 
antagonist and reuptake inhibitor (SARI), which is a second 
generation antidepressant compound belonging to the class of 
phenylpiperazine. The drug showing antidepressant activity is due 
to the blockage of serotonin reuptake by inhibiting serotonin 
reuptake pump at the presynaptic neuronal membrane. Trazodone 
shows its therapeutic actions through 5-HT2A receptors[1]. 
Trazodone also induces anti-anxiety and sleep-inducing effects. The 
mechanism of trazodone hydrochloride’s antidepressant action in 
man is not fully understood. In animals, trazodone selectively 
inhibits its serotonin uptake by brain synaptosomes and potentiates 
the behavioral changes induced by the serotonin precursor, 5-
hydroxytryptophan. Trazodone is not a monoamine oxidase 
inhibitor and, unlike amphetamine-type drugs, does not stimulate 
the central nervous system.  
In humans, trazodone hydrochloride is well absorbed after oral 
administration without selective localization in any tissue. When 
trazodone hydrochloride is taken shortly after ingestion of food, 
there may be an increase in the amount of drug absorbed, a decrease 
in maximum concentration and a lengthening in the time to 
maximum concentration. Peak plasma levels occur approximately 
one hour after dosing when trazodone hydrochloride is taken on an 
empty stomach or two hours after dosing when taken with food. In 
vitro studies in human liver microsomes show that trazodone is 
metabolized to an active metabolite, m-chlorophenylpiperazine 
(mCPP) by cytochrome P450 3A4 (CYP3A4). Other metabolic 
pathways that may be involved in metabolism of trazodone have not 
been well characterized. In some patients trazodone may 
accumulate in the plasma. 
Several analytical methods that have been reported for the 
determination of Trazodone in biological fluids such as 
spectrophotometry, ion-selective electrode, colorimetry, HPLC, 
capillary gas chromatography, GC-MS/MS[3] and LC-MS/ MS. 
Recently, improved analytical methods by LC-MS/MS enabled the 
detect ability of the drug to low nano gram levels (10 ng / mL) in 
human plasma. These methods are either liquid-liquid extraction[2] 
or SPE extraction[1] & also not sensitive. Due to the low 
quantification requirement & cost effectiveness, it is necessary to 
develop a simple, specific, selective, sensitive, cost effective, robust 
and rugged method for the quantification of trazodone in human 
plasma at low nano gram levels (5 ng / mL). 
This article describes a simple, sensitive, cost effective and specific 
method for the determination of trazodone in human plasma using 
LC-MS/MS. The assay allows the quantification of trazodone at a 
concentration of as low as 5 ng / mL in human plasma. The proposed 
method is a high throughput LC-MS/MS method using protein 
precipitation extraction, where precision, accuracy and stability 
[freeze thaw, bench top, dry extract stability, auto sampler stability 
and long term stability (305 days) in plasma] are demonstrated 
through the validation data. This method provides excellent 
specificity and linearity over the range of 5.230 ng / mL to 3025.166 
ng / mL of trazodone. This method has been used for the analysis of 
more than 5000 plasma samples from human volunteers. The 
method is very sensitive and involves simpler and selective 
extraction method for the estimation of trazodone in plasma 
samples compared to the previously reported methods. 
MATERIALS AND METHODS  
Materials  
Trazodone Hydrochloride working standard was provided by Astron 
research Limited, Ahmedabad, India. Internal Standard Trazodone 
D6 Hydrochloride was procured from Clearsynth lab limited, 
Mumbai, India. Methanol (HPLC grade) was purchased from Merck, 
India. Water (Ultrapure) was generated inhouse through milli Q 
system, Ammonium formate (GR grade) was purchased from Acros, 
India and formic acid (Emparta Grade) was purchased from Merck, 
India. Drug free plasma was obtained from Prathama Blood Center, 
Ahmedabad, India. 
Instrumentation and Equipments 
Mass spectrometric analysis was performed on a AB SCIEX API 
3200(LC-MS/MS) equipped with atmospheric pressure ionization 
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interface source, manufactured by MDS Sciex, Canada, attached to a 
high performance liquid chromatography, manufactured by 
Simadzu, Japan, equipped with CTO-10 ASvp column oven, LC-10 
ADvp pump and SIL-HTc auto sampler. Chromatography was carried 
out on an Eclipse XDB-C8 5µm 4.6x150 mm column. 
The data acquisition was achieved using Analyst 14.2 software. 
Samples were centrifuged in a refrigerated centrifuge (Multifuge 3 S-
R+) supplied by Thermo scientific, Germany. 
Chromatographic condition 
The samples were analyzed on an Eclipse XDB-C8 5µm 4.6x150 mm 
column. A mobile phase consisting of 70:30 mixture of methanol: 2 
mM ammonium formate buffer (pH 3.0) was used with a flow rate of 
1.0 mL / min at 40°C under isocratic conditions. The auto sampler 
was set at 4°C and the injection volume was 2 μL. The expected RT 
for the IS and the drug were 1.61 min and 1.62 min respectively and 
the total run time for the analysis was 2.5 min. 
Mass spectrometric condition 
Atmospheric pressure ionization (API) mass spectra were obtained 
by scanning parent ion scan (MS) and product ion scan (MS/MS) 
indicated positive molecular ion (M + H)+ for Trazodone and 
Trazodone d6 (ISTD). Different polarities were employed but the 
highest product ion intensities were obtained using positive 
ionization for trazodone and internal standard (IS). The parent ion 
of trazodone was obtained at 372.00 amu and that of internal 
standard (IS) was at 378.20 amu. The product ion (MS/MS) spectra 
indicated that the compounds undergo different collision induced 
dissociation & collision active dissociation. The MS/MS spectra for 
trazodone showed a major product ion at 176.10 amu and the 
internal standard (IS) showed a high intense product ion at 182.10 
amu. The molecular ion and product ion were selected for further 
quantification because of their greater selectivity, specificity and 
sensitivity. 
The trazodone and internal standard were monitored in the positive 
ion mode using Multiple Reaction Monitoring (MRM) transitions of 
m/z 372.00 → 176.10 and m/z 378.20 → 182.10 respectively with 
dwell times of 300 msec for each of the transitions. The mass 
detection was obtained at unit mass resolution for all channels. 
Quantification of trazodone in human plasma is based on the peak-
area ratios of trazodone versus its internal standard (IS). 
The typical mass parameters are summarized in Table 1. 
 
Table 1: It shows mass spectrometry parameters 




Nebulizer gas (GS1) 50.00 50.00 
Auxiliary gas (GS2) 50.00 50.00 




Ion spray voltage (IS) 5500.0 5500.0 
Temperature (TEM) 400 400 
De clustering potential (DP) 55.00 55.00 
Entrance potential (EP) 10.00 10.00 
Cell Entrance Potential 
(CEP) 
20.99 18.06 
Collision Energy (CE) 35.00 35.00 
Cell exit potential (CXP) 3.00 3.00 
 
Preparation of calibration curve (CC) and quality control (QC) 
samples 
Stock solution of trazodone (1000 μg / mL) was prepared using 
methanol:water (50:50) solution as diluent. Spiking solutions for CC 
and QC were prepared from the stock solution by adequate serial 
dilutions using methanol:water (50:50) solution. Stock solution of 
trazodone d6 (1000 µg / mL) was prepared using methanol as 
solvent. The IS spiking solution (1000 ng / mL) was prepared by 
diluting the stock with methanol.  
Calibration standards were prepared by spiking appropriate volume 
of the respective spiking solutions to control plasma to achieve eight 
different concentrations from 5.0 ng / mL to 3000.00 ng / mL of 
trazodone. The standards were then stored in the refrigerator. 
Quality control (QC) samples were prepared by spiking appropriate 
volume of the respective spiking solutions to control plasma to 
achieve four different concentrations at LOQ, low, medium and high 
levels for trazodone. The QC samples were then stored in the freezer 
below -65°C. 
Sample processing for analysis 
The frozen samples were thawed in a water bath at room 
temperature. The thawed samples were vortexed to ensure 
complete mixing of the contents. 0.1 mL of each plasma sample was 
transferred into pre-labeled tubes and 50 μL of internal standard 
(IS) solution (about 1000 ng / mL) was added to each tube and 
vortexed to ensure complete mixing. After the addition of 0.5 mL of 
methanol was added to each tube and vortexed for 3.0 minutes to 
ensure complete mixing, the samples were centrifuged at rcf 4000 ± 
150 for 10 minutes at 10°C. The supernatant was transferred into an 
appropriate vial for analysis. 
RESULTS  
Chromatography 
The peaks of Trazodone and Trazodone-d6 (ISTD) were free from 
any overlapping peaks and any closely eluting peaks and 
appropriately integrated in a manner that adjacent peaks do not 
influence the analyte and ISTD area.  
Representative chromatograms are shown in Figures 1 to 4. 
 
 




Eight batches of human blank plasma (six normal, one haemolysed 
and one lipemic) containing K2EDTA as an anticoagulant were 
evaluated for selectivity and no interference was observed at the 
retention times and transitions of Trazodone and Trazodone-d6 
(ISTD) in any of the human blank plasma batches 
Sample Name: "MV(I)-012-13_P&AII_10"    Sample ID: "STD1"    File: "251013_P&AII_SET1.wiff"
Peak Name: "A1"    Mass(es): "372.0/176.1 amu"
Comment: ""    Annotation: ""
Sample Index:      10     
Sample Type:     Standard  
Concentration:     5.203    ng/mL  
Calculated Conc:   5.175    ng/mL  
Acq. Date:       10/25/2013  
Acq. Time:       8:59:43 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    5.00   cps
Area Threshold:  250.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       1.658   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.650   min
Area:            2246   counts
Height:         4.73e+002  cps
Start Time:         1.53   min
End Time:           1.77   min


































Sample Name: "MV(I)-012-13_P&AII_10"    Sample ID: "STD1"    File: "251013_P&AII_SET1.wiff"
Peak Name: "ISTD(IS)"    Mass(es): "378.2/182.1 amu"
Comment: ""    Annotation: ""
Sample Index:      10     
Sample Type:     Standard  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       10/25/2013  
Acq. Time:       8:59:43 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    5.00   cps
Area Threshold:  500.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.65   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.639   min
Area:          160820   counts
Height:         3.18e+004  cps
Start Time:         1.48   min
End Time:           1.93   min
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Fig. 2: It shows a representative chromatogram of Blank plasma 
 
 
Fig. 3: It shows a representative chromatogram of blank + ISTD 
 
Linearity 
A linear equation was judged to produce the best fit for the 
concentration vs. area response relationship. The regression type 
was 1/concentration² and peak area ratio for an 8-point calibration 
curve was found linear from 5.203 ng / mL to 3025.166 ng / mL. The 
coefficient of determination (r²) was consistently greater than 0.99 
during the course of method validation. Calibration curve was 
processed and run along with each batch that was analyzed on 
consecutive days using freshly prepared solution each day. The 
between-batch variability in the calibration curves was reported 
with the coefficients of variation (CVs) and accuracy obtained during 
method validation. 
 
Fig. 4: It shows a representative chromatogram of ULQC 
 
The range of precision and accuracy of the back-calculated 
concentrations of the standard curve points was from 0.1 % to 2.4 % 
and from 97.3 % to 102.1 % respectively. 
Representative calibration curve is shown in Figures 5. 
 
 
Fig. 5: It shows a representative regression analysis of a 
calibration curve 
 
Sensitivity & Limit of detection 
The lower limit of quantification was 5.203 ng / mL. The limit of 
detection of the method was 0.656 ng / mL. 
Representative chromatograms are shown in Figures 6. 
Precisions and Accuracy 
Precision of the assay was measured by the percent coefficient of 
variance over the concentration range of limit of quantification, low, 
medium, high and dilution quality control samples of Trazodone 
Sample Name: "MV(I)-012-13_P&AII_01"    Sample ID: "STD_BLANK"    File: "251013_P&AII_SET1.wiff"
Peak Name: "A1"    Mass(es): "372.0/176.1 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc: No Intercept           
Acq. Date:       10/25/2013  
Acq. Time:       8:30:42 PM  
 
Modified:           No    




























































Sample Name: "MV(I)-012-13_P&AII_01"    Sample ID: "STD_BLANK"    File: "251013_P&AII_SET1.wiff"
Peak Name: "ISTD(IS)"    Mass(es): "378.2/182.1 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       10/25/2013  
Acq. Time:       8:30:42 PM  
 
Modified:           No    
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Sample Name: "MV(I)-012-13_P&AII_02"    Sample ID: "STD_ZERO"    File: "251013_P&AII_SET1.wiff"
Peak Name: "A1"    Mass(es): "372.0/176.1 amu"
Comment: ""    Annotation: ""
Sample Index:       2     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.000    ng/mL  
Acq. Date:       10/25/2013  
Acq. Time:       8:33:53 PM  
 
Modified:           No    

























































Sample Name: "MV(I)-012-13_P&AII_02"    Sample ID: "STD_ZERO"    File: "251013_P&AII_SET1.wiff"
Peak Name: "ISTD(IS)"    Mass(es): "378.2/182.1 amu"
Comment: ""    Annotation: ""
Sample Index:       2     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       10/25/2013  
Acq. Time:       8:33:53 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    5.00   cps
Area Threshold:  500.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.65   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.639   min
Area:          163703   counts
Height:         3.28e+004  cps
Start Time:         1.50   min
End Time:           1.92   min
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Sample Name: "MV(I)-012-13_P&AII_15"    Sample ID: "HQC_1002-A"    File: "251013_P&AII_SET1.wiff"
Peak Name: "A1"    Mass(es): "372.0/176.1 amu"
Comment: ""    Annotation: ""
Sample Index:      15     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc: 2379.449    ng/mL  
Acq. Date:       10/25/2013  
Acq. Time:       9:15:46 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    5.00   cps
Area Threshold:  250.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       1.658   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.650   min
Area:         1029479   counts
Height:         2.03e+005  cps
Start Time:         1.53   min
End Time:           2.14   min































Sample Name: "MV(I)-012-13_P&AII_15"    Sample ID: "HQC_1002-A"    File: "251013_P&AII_SET1.wiff"
Peak Name: "ISTD(IS)"    Mass(es): "378.2/182.1 amu"
Comment: ""    Annotation: ""
Sample Index:      15     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       10/25/2013  
Acq. Time:       9:15:46 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    5.00   cps
Area Threshold:  500.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.65   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.640   min
Area:          165807   counts
Height:         3.31e+004  cps
Start Time:         1.53   min
End Time:           1.93   min











































251013_P&AII.rdb (A1): "Linear" Regression ("1  / (x * x)" weighting): y = 0.00261 x + 0.000464 (r = 0.9999)
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during the course of the method validation. Within-batch precision 
(Intra-day precision) ranged from 0.4 % to 5.7 %. Between-batch 
precision [Inter-day precision (Global statistics)] ranged from 1.0 % 
to 6.5 %. 
 
 
Fig. 6: It shows a representative chromatogram of limit of 
detection 
 
 Accuracy of the assay was defined as the absolute value of the ratio 
of the mean back-calculated values of the quality control samples to 
their respective nominal values, expressed in percentage. Within-
batch accuracy (Intra-day accuracy) ranged from 102.0 % to 105.8 
%. Between-batch accuracy [Inter-day accuracy (Global statistics)] 
ranged from 101.4 % to 107.2 %. 
Stability 
Six replicates of low and high quality control samples were used for 
the determination of the processed sample stability. Results 
indicated that the difference in the back-calculated concentration 
from time 0.0 hr to time 73.0 hrs between 2 and 8 °C was -0.3% for 
LQC and 2.1% for HQC. This showed that processed samples were 
stable for at least 73.0 hrs when stored between 2 and 8 °C.  
The results of long term and short term stock solution stability 
indicated that the stock solutions of Drug and IS were stable for 11.0 
hrs at room temperature and for 06 days while stored between 2 
and 8 °C. The long-term stability of the Drug in plasma showed that 
the spiked Drug samples were stable for at least 61 days after 
storage at –65.0 °C in a deep freezer. The freeze-thaw stability 
results indicated that the Drug was stable after going through three 
freeze-thaw cycles. Furthermore, the results of bench top stability 
indicated that the processed samples were stable for at least 9.0 hrs 
at room temperature.  
Recovery (extraction yield) 
Trazodone 
The mean % recovery for the low, medium and high quality control 
samples was 88.6 %, 86.4 % and 88.6 % respectively. 
Trazodone D6 
The mean recovery for Trazodone-d6 (ISTD) was 70.3 %. 
Robustness and Ruggedness 
The robustness and ruggedness of the method was evaluated 
through long batch of 150 samples. 
Matrix effect 
The CV (%) for IS normalized matrix factor in ten lots was 0.9 for 
HQC & 3.1 for LQC. Based on the obtained results it can be concluded 
that, no significant ion suppression or enhancement was observed 
during ionization in mass spectrometric detector. 
Carryover 
No significant carryover was observed when processed blank human 
plasma was injected immediately after the extracted high standards 
and when the reconstituted solution was injected immediately after 
the non-extracted aqueous high standard. 
The method validation parameters are summarized in Table 2. 
DISCUSSION 
Due to the requirement for the quantification of trazodone in human 
plasma at low nano gram levels this simple, specific, selective, 
sensitive, cost effective, robust and rugged method for the 
quantification of trazodone in human plasma at low nano gram 
levels (5 ng / mL) has been developed. Other reported method of 
trazodone involves several critical steps of extraction and cleaning 
of the samples and hence, is very time consuming. Also the 
sensitivity of the method was not at par. The sensitivity of the drug 
observed in various HPLC/ UV, LC-MS/MS methods published until 
now is inadequate for pharmacokinetic studies and monitoring of 
the therapeutic drugs. Composition of the mobile phase was found to 
be a critical factor for achieving good shape of the chromatographic 
peak. In the present method 2 mM ammonium formate was selected 
as the buffer and methanol as the organic modifier. During the 
development, it was found the signal of the analyte dropped 
significantly after the usages of other buffers like formic acid, 
ammonium acetate, acetic acid & ammonium hydroxide.  
Also several analytical columns were tried to obtained good 
chromatography. Finally good chromatography with lower retention 
time was obtained in column of Zorbax Eclipse XDB C-8 150X4.6 
mm, 5µ using injection volume of 2µL. Various extraction techniques 
which include protein precipitation, liquid-liquid extraction and 
solid phase extraction were employed during method development. 
The liquid-liquid extraction technique using different solvents and 
back -extraction methods also resulted in low recovery of the drug. 
Furthermore, the solid phase extraction method involves usages of 
SPE cartridges, long extraction time and critical extractions steps. As 
trazodone has a very high protein binding, thus the precipitation 
methods, using different precipitating agents such as acetonitrile, 
methanol, acidic-basic acetonitrile / methanol solution were also 
tried.Hence a method using protein precipitation extraction was 
adopted utilizing methanol as precipitating agent. Good recovery, 
better precision & accuracy and very minimal ion suppression or 
matrix effect was observed during the validation of the method. In 
this method, sensitivity, linearity and stability improved 
considerably from the reported method. Tedious SPE & 
derivatization steps were avoided. This method was validated for 
calibration range of 5.203 ng / ml to 3025.166 ng / ml, which would 
be sufficient for the analysis of sample from a single dose (100 mg) 
administration to humans. 
CONCLUSION 
The method described here for the assay of trazodone in plasma is 
found to be simple, specific, selective, sensitive, cost effective, robust 
and rugged during a method validation. This demonstrates the 
suitability of this analytical method for the use in bioavailability 
studies. The method is proved to be suitable for the clinical 
investigation of trazodone pharmacokinetics and offers higher 
specificity, speed and greater sensitivity over the previously 
reported methods. 
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Sample Name: "MV(I)-012-13_LOD_01_10"    Sample ID: "LOD_03-B"    File: "261013_LOD_01_SET1.wiff"
Peak Name: "A1"    Mass(es): "372.0/176.1 amu"
Comment: ""    Annotation: ""
Sample Index:      10     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    0.00    ng/mL  
Acq. Date:       10/26/2013  
Acq. Time:       4:38:57 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.00   cps
Area Threshold:  100.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       1.658   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.646   min
Area:             421   counts
Height:         1.02e+002  cps
Start Time:         1.58   min
End Time:           1.76   min
































Sample Name: "MV(I)-012-13_LOD_01_10"    Sample ID: "LOD_03-B"    File: "261013_LOD_01_SET1.wiff"
Peak Name: "ISTD(IS)"    Mass(es): "378.2/182.1 amu"
Comment: ""    Annotation: ""
Sample Index:      10     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       10/26/2013  
Acq. Time:       4:38:57 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    5.00   cps
Area Threshold:  500.00   cps
Num. Smooths:       4     
Sep. Width:         1.00  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.65   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    1.635   min
Area:          178823   counts
Height:         3.61e+004  cps
Start Time:         1.53   min
End Time:           1.91   min
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Table 2: It shows a Validation Summary 
S. No. Validation Parameters Results / Data 
01 Linearity (Range) 5.203 to 3025.166 ng / mL 
02 Coefficient of determination Greater than 0.99 
03 Limit of quantification 5.203 ng / mL 
04 Limit of detection  0.656 ng / mL 
05 Selectivity No interference at the retention times and transitions of drug and internal 
standard. 
06 Precision Between-batch (Inter-day 
precision) 
1.0 % to 6.5 % 
Within-batch (Intra-day 
precision) 
0.4 % to 5.7 %. 
07 Accuracy Between-batch (Inter-day 
accuracy) 
101.4 % to 107.2 %. 
Within-batch (Intra-day 
accuracy) 
102.0 % to 105.8 % 
08 Robustness and Ruggedness experiment  Method is rugged and robust (up to 150 injections) 
09 Recovery (drug) LQC, MQC & HQC 88.6 %, 86.4 % and 88.6 % 
10 Recovery (ISTD) 70.3 % 
11 Matrix effect No significant ion suppression or enhancement 
12 Stock solution stability (Short term ) 11.0 hours (at room temperature) 
13 Stock solution stability (long term ) 06 days (within 2 to 8°C) 
14 Auto sampler / Wet extract stability 73.0 hours (within 2 to 8°C) 
15 Freeze and thaw stability 4 cycles at -65 ± 10°C 
16 Bench top stability  9.0 hours (at room temperature) 
17 Long term stability of drug in plasma  61 Days at -65±10°C 
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